Development of Inhibitors of the IGF-IR/PI3K/Akt/mTOR Pathway

Reviews on Recent Clinical Trials

Volumn 5, Issue 3, 2010, Pages 189-208

  Hixon, Mary L ^a   Paccagnella, Luisa ^b   Millham, Robert ^b   Perez Olle, Raul ^c   Gualberto, Antonio ^a,b  

^a BROWN UNIVERSITY   (United States)

^b PFIZER INC   (United States)

^c Pfizer Ltd   (United States)

Author keywords

Akt; IGF IR; mTOR; PI3K

Indexed keywords

1 (1 CYANO 1 METHYLETHYL) 3 METHYL 8 (3 QUINOLINYL)IMIDAZO[4,5 C]QUINOLIN 2(1H,3H) ONE; 4 DIALLYLAMINOMETHYLENE 1,3,4,7,10,11,12,13,14,15,16,17 DODECAHYDRO 6 HYDROXY 1 METHOXYMETHYL 10,13 DIMETHYL 3,7,17 TRIOXO 2 OXACYCLOPENTA[A]PHENANTHREN 11 YL ACETATE; ABI 009; AMG 479; AVE 1642; AZD 8055; BGT 226; BMS 754807; CIXUTUXUMAB; CP 751871; EVEROLIMUS; FIGITUMUMAB; IMC A 12; MAMMALIAN TARGET OF RAPAMYCIN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MK 0646; MKC 1; OSI 027; OSI 906; PERIFOSINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PROTEIN KINASE B INHIBITOR; R 1507; RIDAFOROLIMUS; ROBATUMUMAB; RX 0201; SCH 717454; SOMATOMEDIN; SOMATOMEDIN C RECEPTOR; TEMSIROLIMUS; UNCLASSIFIED DRUG; UNINDEXED DRUG; XL 228;

ADRENAL HEMORRHAGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANEMIA; ANOREXIA; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; BLOOD TOXICITY; CANCER RESEARCH; CELL MOTILITY; CELL PROLIFERATION; CLINICAL TRIAL; DEPRESSION; DESQUAMATION; DIABETES MELLITUS; DIARRHEA; DRUG ACTIVITY; DRUG MECHANISM; DRUG RESEARCH; DRUG WITHDRAWAL; DYSPNEA; EDEMA; ENZYME INHIBITION; FATIGUE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERGLYCEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; KIDNEY FAILURE; LEUKOPENIA; LUNG EMBOLISM; MACULOPAPULAR RASH; MALIGNANT NEOPLASTIC DISEASE; MOUTH DISEASE; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; NAUSEA; NEGATIVE FEEDBACK; NEUTROPENIA; ONCOLOGY; PAIN; PLEURA EFFUSION; PNEUMONIA; PRIORITY JOURNAL; RASH; SIDE EFFECT; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CLINICAL TRIALS AS TOPIC; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; NEOPLASMS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; RECEPTOR, IGF TYPE 1; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TRANS-ACTIVATORS;

EID: 78650001661     PISSN: 15748871     EISSN: None     Source Type: Journal    
DOI: 10.2174/157488710792007329     Document Type: Article

References (113)

1. Ma WW, Adjei AA. Novel agents on the horizon for cancer therapy. CA 2009; 59: 111-137.
2. Sachdev D, Yee D. Disrupting insulin-like growth factor signaling as a potential cancer therapy. Mol Cancer Ther 2007; 6: 1-12.
3. Gottesman MM. Mechanisms of cancer drug resistance. Ann Rev Med 2002; 53: 615-627.
4. Kawauchi K, Ogasawara T, Yasuyama M et al. Regulation and Importance of the PI3K/Akt/mTOR signaling pathway in hematologic malignancies. anticancer agents. Med Chem 2009; [Epub ahead of print].
5. Di CS, Baselga J. Phosphoinositide 3-kinase mutations in breast cancer: a good activating mutation? Clin Cancer Res 2009; 15: 5017-5019.
6. Samani AA, Yakar S, LeRoith D et al. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007; 28: 20-47.
7. Jones JI, Clemmons DR. Insulin-like growth factors and their binding proteins: biological actions. Endocr Rev 1995; 16: 3-34.
8. Kelley KM, Schmidt KE, Berg L, et al. Comparative endocrinology of the insulin-like growth factor-binding protein. J Endocrinol 2002; 175: 3-18.
9. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 1978; 253: 2769-2776.
10. De Meyts P, Whittaker J. Structural biology of insulin and IGF1 receptors: implications for drug design. Nat Rev Drug Discov 2002; 1: 769-783.
11. Ullrich A, Gray A, Tam AW, et al. Insulin-like growth factor I receptor primary structure: comparison with insulin receptor suggests structural determinants that define functional specificity. EMBO J 1986; 5: 2503-2512.
12. Surinya KH, Forbes BE, Occhiodoro F et al. An investigation of the ligand binding properties and negative cooperativity of soluble insulin-like growth factor receptors. J Biol Chem 2008; 283: 5355-5363.
13. Hartog H, Wesseling J, Boezen HM et al. The insulin-like growth factor 1 receptor in cancer: old focus, new future. Eur J Cancer 2007; 43: 1895-1904.
14. Le Roith D, Bondy C, Yakar S, et al. The somatomedin hypothesis: 2001. Endocr Rev 2001; 22: 53-74.
15. Ludwig T, Eggenschwiler J, Fisher P et al. Mouse mutants lacking the type 2 IGF receptor (IGF2R) are rescued from perinatal lethality in Igf2 and Igf1r null backgrounds. Dev Biol 1996; 177: 517-535.
16. Chitnis MM, Yuen JSP, Protheroe AS, et al. The type 1 insulin-like growth factor receptor pathway. Clin Cancer Res 2008; 14: 6364-6370.
17. Nitert MD, Chisalita SI, Olsson K, et al. IGF-I/insulin hybrid receptors in human endothelial cells. Mol Cell Endocrinol 2005; 229: 31-37.
18. Tricoli JV, Rall LB, Karakousis CP, et al. Enhanced levels of insulin- like growth factor messenger RNA in human colon carcinomas and liposarcomas. Cancer Res 1986; 46: 6169-6173.
19. Chung CK, Antoniades HN. Expression of c-sis/platelet-derived growth factor B, insulin-like growth factor I, and transforming growth factor alpha messenger RNAs and their respective receptor messenger RNAs in primary human gastric carcinomas: in vivo studies with in situ hybridization and immunocytochemistry. Cancer Res 1992; 52: 3453-3459.
20. Bergmann U, Funatomi H, Yokoyama M et al. Insulin-like growth factor I overexpression in human pancreatic cancer: evidence for autocrine and paracrine roles. Cancer Res 1995; 55: 2007-2011.
21. Cariani E, Lasserre C, Seurin D et al. Differential expression of insulin-like growth factor II mRNA in human primary liver cancers, benign liver tumors, and liver cirrhosis. Cancer Res 1988; 48: 6844-6849.
22. Yee D, Paik S, Lebovic GS et al. Analysis of insulin-like growth factor I gene expression in malignancy: evidence for a paracrine role in human breast cancer. Mol Endocrinol 1989; 3: 509-517.
23. Yee D, Morales FR, Hamilton TC, et al. Expression of insulin-like growth factor I, its binding proteins, and its receptor in ovarian cancer. Cancer Res 1991; 51: 5107-5112.
24. Pollak M. Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev Cancer 2008; 8: 915-928.
25. Allen GW, Saba C, Armstrong EA et al. Insulin-like growth factor- I receptor signaling blockade combined with radiation. Cancer Res 2007; 67: 1155-1162.
26. Jones HE, Gee JM, Hutcheson IR et al. Growth factor receptor interplay and resistance in cancer. Endocr Relat Cancer 2006; 13: S45-S51.
27. Wiseman LR, Johnson MD, Wakeling AE et al. Type I IGF receptor and acquired tamoxifen resistance in oestrogen-responsive human breast cancer cells. Eur J Cancer 1993; 29A: 2256-2264.
28. Timp W, Levchenko A, Feinberg AP. A new link between epigenetic progenitor lesions in cancer and the dynamics of signal transduction. Cell Cycle 2009; 8: 383-390.
29. Pavelic K, Bukovic D, Pavelic J. The role of insulin-like growth factor 2 and its receptors in human tumors. Mol Med 2002; 8: 771-780.
30. Byron SA, Horwitz KB, Richer JK, et al. Insulin receptor substrates mediate distinct biological responses to insulin-like growth factor receptor activation in breast cancer cells. Br J Cancer 2006; 95: 1220-1228.
31. Pandini G, Vigneri R, Costantino A et al. Insulin and insulin-like growth factor-I (IGF-I) receptor overexpression in breast cancers leads to insulin/IGF-I hybrid receptor overexpression: evidence for a second mechanism of IGF-I signaling. Clin Cancer Res 1999; 5: 1935-1944.
32. Riedemann J, Macaulay VM. IGF1R signalling and its inhibition. Endocr Relat Cancer 2006; 13: S33-S43.
33. Frasca F, Pandini G, Sciacca L, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008; 114: 23-37.
34. Karp DD, Paz-Ares LG, Novello S et al. Phase II study of the efficacy of the anti-insulin-like growth factor type 1 receptor antibody CP-751,871 in combination with paclitaxel and carboplatin in previously untreated, locally advanced, or metastatic non-small cell lung cancer. J Clin Oncol 2009; 27: 2516-2522.
35. Markman B, Atzori F, Perez-Garcia J, et al. Status of P13K inhibition and biomarker development in cancer therapeutics. Ann Oncol 2009; [Epub August 27].
36. Yap TA, Garrett MD, Walton MI, et al. Targeting the PI3K-AKTmTOR pathway: progress, pitfalls, and promises. Curr Opin Pharmacol 2008; 8: 393-412.
37. Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008; 27: 5497-5510.
38. LoPiccolo J, Blumenthal GM, Bernstein WB, et al. Targeting the PI3K/Akt/mTOR pathway: effective combinations and clinical considerations. Drug Resist Update 2008, 11: 32-50.
39. Garofalo RS, Orena SJ, Rafidi K et al. Severe diabetes, agedependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKB beta. J Clin Invest 2003; 112: 197-208.
40. Yang ZZ, Tschopp O, Baudry A et al. Physiological functions of protein kinase B/Akt. Biochem Soc Trans 2004; 32: 350-354.
41. Fasolo A, Sessa C. mTOR inhibitors in the treatment of cancer. Expert Opin Investig Drugs 2008; 17: 1717-1734.
42. Shayesteh L, Lu Y, Kuo WL, et al. PIK3CA is implicated as an oncogene in ovarian cancer. Nat Genet 1999; 21: 99-102.
43. Ma YY, Wei SJ, Lin Y, et al. PIK3CA as an oncogene in cervical cancer. Oncogene 2000; 19: 2739-2744.
44. Zhao L, Vogt PK. Class I PI3K in oncogenic cellular transformation. Oncogene 2008; 27: 5486-5496.
45. Philp AJ, Campbell IG, Leet C et al. The phosphatidylinositol 3'- kinase p85alpha gene is an oncogene in human ovarian and colon tumors. Cancer Res 2001; 61: 7426-7429.
46. Kalinsky K, Jacks LM, Heguy A, et al. PIK3CA mutation associates with improved outcome in breast cancer. Clin Cancer Res 2009; 15: 5049-5059.
47. Saal LH, Johansson P, Holm K, et al. Poor prognosis in carcinoma is associated with a gene expression signature of aberrant PTEN tumor suppressor pathway activity. Proc Natl Acad Sci USA 2007; 104: 7564-7569.
48. Soung YH, Lee JW, Nam SW et al. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas. Oncology 2006; 70: 285-289.
49. Kong D, Yamori T. Advances in development of phosphatidylinositol 3-kinase inhibitors. Curr Med Chem 2009; 16: 2839-2854.
50. Wysocki PJ. mTOR in renal cell cancer: modulator of tumor biology and therapeutic target. Expert Rev Mol Diagn 2009; 9: 231-241.
51. Sarbassov DD, Guertin DA, Ali SM et al. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 2005; 307: 1098-1001.
52. Jiang BH, Liu LZ. Role of mTOR in anticancer drug resistance: perspectives for improved drug treatment. Drug Resist Update 2008, 11: 63-76.
53. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nat Rev Cancer 2002; 2: 489-501.
54. Panasyuk G, Nemazanyy I, Zhyvoloup A et al. The mTOR splicing isoform promotes cell proliferation and tumorigenesis. J Biol Chem 2009; 284: 30807-30814.
55. Haluska P, Shaw HM, Batzel GN et al. Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors. Clin Cancer Res 2007; 13: 5834-5840.
56. Lacy MQ, Alsina M, Fonseca R, et al. Phase I, pharmacokinetic and pharmacodynamic study of the anti-insulinlike growth factor type 1 Receptor monoclonal antibody CP-751,871 in patients with multiple myeloma. J Clin Oncol 2008; 26: 3196-3203.
57. Gualberto A, Dolled-Filhart MP, Hixon M, et al. Molecular basis for sensitivity to figitumumab (CP-751,871). J Clin Oncol 2009; 27: 8091s.
58. Hixon M, Gualberto A, Demers L et al. (2009) Correlation of plasma levels of free insulin-like growth factor 1 and clinical benefit of the IGF-IR inhibitor, figitumumab (CP-751,871). J Clin Oncol 2009; 27: 3539s.
59. Tolcher AW, Sarantopoulos J, Patnaik A, et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol 2009; 27: 5800-5807.
60. Atzori F, Tabernero J, Cervantes A, et al. A phase I, pharmacokinetic (PK) and pharmacodynamic (PD) study of weekly (qW) MK- 0646, an insulin-like growth factor-1 receptor (IGF1R) monoclonal antibody (MAb) in patients (pts) with advanced solid tumors. J Clin Oncol 2006; 26: 3519s.
61. Hidalgo M, Tirado Gomez M, Lewis N et al. A phase I study of MK-0646, a humanized monoclonal antibody against the insulinlike growth factor receptor type 1 (IGF1R) in advanced solid tumor patients in a q2 wk schedule. J Clin Oncol 2008; 26: 3519s.
62. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009; 28(34): 3009-3021.
63. Lee FY, Camuso A, Castenada S, et al. Preclinical efficacy evaluation of ixabepilone (BMS-247550) in combination with cetuximab or capecitabine in human colon and lung carcinoma xenografts. J Clin Oncol 2006; 24: 12017s.
64. Carden CP, Frentzas S, Langham M et al. Preliminary activity in adrenocortical tumor (ACC) in phase I dose escalation study of intermittent oral dosing of OSI-906, a small-molecule insulin-like growth factor-1 receptor (IGF-1R) tyrosine kinase inhibitor in patients with advanced solid tumors. J Clin Oncol 2009; 27: 3544s.
65. Lindsay CR, Chan E, Evans TR et al. Phase I dose escalation study of continuous oral dosing of OSI-906, an insulin like growth factor- 1 receptor (IGF-1R) tyrosine kinase inhibitor, in patients with advanced solid tumors. J Clin Oncol 2009; 27: 2559s.
66. Cho DC, Figlin RA, Flaherty KTD et al. A phase II trial of perifosine in patients with advanced renal cell carcinoma (RCC) who have failed tyrosine kinase inhibitors (TKI). J Clin Oncol 2009; 27: 15s, abstr 5101.
67. Campos LT, Nemunaitis J, Stephenson J. Phase II study of single agent perifosine in patients with hepatocellular carcinoma (HCC). J Clin Oncol 2009; 27: 15505s.
68. Conley AP, Araujo D, Ludwig J, et al. A randomized phase II study of perifosine (P) plus imatinib for patients with imatinibresistant gastrointestinal stromal tumor (GIST). J Clin Oncol 2009; 27: 10563s.
69. Vukelja S, Richards D, Campos LT et al. Randomized phase II study of perifosine in combination with capecitabine versus capecitabine alone in patients with second- or third-line metastatic colon cancer. J Clin Oncol 2009; 27: 4081s.
70. Birch R, Chawla S, Nemunaitis J et al. Perifosine (P) as an active agent in the treatment of patients with advanced sarcoma. J Clin Oncol 2007; 25: 10059s.
71. Stephenson J, Schreeder M, Waples J. Perifosine (P), active as a single agent for renal cell carcinoma (RCC), now in phase I trials combined with tyrosine kinase inhibitors (TKI). J Clin Oncol 2007; 25: 15622s.
72. Marshall J, Posey J, Hwang J et al. A phase I trial of RX-0201 (AKT anti-sense) in patients with an advanced cancer. J Clin Oncol 2007; 25: 3564s.
73. Eichhorn PJ, Gili M, Scaltriti M et al. Phosphatidylinositol 3- kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/phosphatidylinositol 3-kinase inhibitor NVPBEZ235. Cancer Res 2008; 68: 9221-9230.
74. Jimeno A, Hong DS, Hecker S et al. Phase I trial of PX-866, a novel phosphoinositide-3-kinase (PI-3K) inhibitor. J Clin Oncol 2009; 27: 3542s.
75. Sarker D, Kristeleit R, Mazina KE et al. A phase I study evaluating the pharmacokinetics (PK) and pharmacodynamics (PD) of the oral pan-phosphoinositide-3 kinase (PI3K) inhibitor GDC-0941. J Clin Oncol 2009; 27: 3538s.
76. Wagner AJ, Van Hoff DH, LoRusso R et al. A first-in-human phase I study to evaluate the pan-PI3K inhibitor GDC-0941 administered QD or BID in patients with advanced solid tumors. J Clin Oncol 2009; 27: 3501s.
77. Papadopoulos KP, Markman B, Tabernero J et al. A phase I doseescalation study of the safety, pharmacokinetics (PK), and pharmacodynamics of XL765, a PI3K/TORC1/TORC2 inhibitor administered orally to patients (pts) with advanced solid tumors. J Clin Oncol 2010; 28: 3030s.
78. Shapiro G, Kwak E, Baselga J et al. Phase I dose-escalation study of XL147, a PI3K inhibitor administered orally to patients with solid tumors. J Clin Oncol 2009; 27: 3500s.
79. Hoffman K, Holmes F, Fraschini G et al. Phase I-II study: triciribine (tricyclic nucleoside phosphate) for metastatic breast cancer. Cancer Chemother Pharmacol 1996; 37: 254-258.
80. Flinn IW, Byrd JC, Furman RR et al. Preliminary evidence of clinical activity in a phase I study of CAL-101, a selective inhibitor of the p1108 isoform of phosphatidylinositol 3-kinase (P13K), in patients with select hematologic malignancies. J Clin Oncol 2009; 27: 3543.
81. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005; 352: 1317-1323.
82. Wienecke R, Fackler I, Linsenmaier U, et al. Antitumoral activity of rapamycin in renal angiomyolipoma associated with tuberous sclerosis complex. Am J Kidney Dis 2006; 48: e27-e29.
83. Sarker D, Reid AH, Yap TA et al. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
84. Fulda S. The PI3K/Akt/mTOR pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets 2009; 9: 729-737.
85. Meric-Bernstam F, Gonzalez-Angulo AM. Targeting the mTOR signaling network for cancer therapy. J Clin Oncol 2009; 27: 2278-2287.
86. Hudes G, Carducci M, Tomczak P et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Eng J Med 2007; 356: 2271-2281.
87. Hess G, Herbrecht R, Romaguera J, et al. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma. J Clin Oncol 2009; 27(23): 3822-3829.
88. Motzer RJ, Escudier B, Oudard S et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo- controlled phase III trial. Lancet 2008; 372: 449-456.
89. Khuri R, Harvey RD, Saba NF et al. Everolimus, an mTOR inhibitor, in combination with docetaxel for recurrent/refractory NSCLC: a phase I study. J Clin Oncol 2009; 27: 8060s.
90. Milton DT, Riely GJ, Azzoli CG et al. Phase I trial of everolimus and gefitinib in patients with advanced nonsmall-cell lung cancer. Cancer 2007; 110: 599-605.
91. Mayer IA, Means-Powell J, Shyr Y et al. A phase Ib trial of erlotinib, an EGFR inhibitor, and everolimus (RAD001), an mTOR inhibitor, in patients with metastatic breast cancer. ASCO 2009 Breast Cancer Symp 2009; Abst 254.
92. Mayer A, Burris HA, Bendell JC et al. A phase I trial of weekly cisplatin, paclitaxel and RAD001, an mTOR inhibitor, in patients with HER2-negative metastatic breast cancer. ASCO 2009 Breast Cancer Symp 2009; Abst 250.
93. Mita MM, Mita AC, Chu QS et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 2008; 26: 361-7.
94. Cho D, Signoretti S, Dabora S et al. Potential histologic and molecular predictors of response to temsirolimus in patients with advanced renal cell carcinoma. Clin Genitourin Cancer 2007; 5: 379-385.
95. Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95: 1148-54.
96. Iwenofu OH, Lackman RD, Staddon AP, et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 21: 231-37.
97. Ferte C, Andre F, Soria JC. Molecular circuits of solid tumors: prognostic and predictive tools for bedside use. Nat Rev Clin Oncol 2010; 7: 367-80.
98. Iwenofu OH, Lackman RD, Staddon AP et al. Phospho-S6 ribosomal protein: a potential new predictive sarcoma marker for targeted mTOR therapy. Mod Pathol 2008; 21: 231-7.
99. Peralba JM, DeGraffenried L, Friedrichs W, et al. Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 2003; 9: 2887-92.
100. Boulay A, Zumstein-Mecker S, Stephan C, et al. Antitumor efficacy of intermittent treatment schedules with the rapamycin derivative RAD001 correlates with prolonged inactivation of ribosomal protein S6 kinase 1 in peripheral blood mononuclear cells. Cancer Res 2004; 64: 252-61.
101. O'Donnell A, Faivre S, Burris HA III, et al. Phase I pharmacokinetic and pharmacodynamic study of the oral mammalian target of rapamycin inhibitor everolimus in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1588-95.
102. Tanaka C, O'Reilly T, Kovarik JM, et al. Identifying optimal biologic doses of everolimus (RAD001) in patients with cancer based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 2008; 26: 1596-602.
103. Tabernero J, Rojo F, Calvo E et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: A phase I tumor pharmacodynamic study in patients with advanced solid tumors. J Clin Oncol 2008; 26: 1603-610.
104. O'Reilly KE, Rojo F, She QB et al. mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 2006; 66: 1500-8.
105. Tamburini J, Chapuis N, Bardet V et al. Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3- kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. Blood 2008; 111: 379-82.
106. Wan X, Harkavy B, Shen N et al. Rapamycin induces feedback activation of Akt signaling through an IGF-1R-dependent mechanism. Oncogene 2007; 26: 1932-40.
107. Coulter DW, Wilkie MB, Moats-Staats BM. Inhibition of IGF-I receptor signaling in combination with rapamycin or temsirolimus increases MYC-N phosphorylation. Anticancer Res 2009; 29: 1943-9.
108. Baumann P, Hagemeier H, Mandl-Weber S et al. Myeloma cell growth inhibition is augmented by synchronous inhibition of the insulin-like growth factor-1 receptor by NVP-AEW541 and inhibition of mammalian target of rapamycin by Rad001. Anticancer Drugs 2009; 20: 259-66.
109. Engelman JA, Chen L, Tan X et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nature Med 2008; 14: 1351-56.
110. Hoeflich KP, O'Brien C, Boyd Z, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009; 15: 4649-64.
111. Wang LH, Chan JL, Li W. Rapamycin together with herceptin significantly increased anti-tumor efficacy compared to either alone in ErbB2 over expressing breast cancer cells. Int J Cancer 2007; 121: 157-64.
112. Zaidi SH, Huddart RA, Harrington KJ. Novel targeted radiosensitisers in cancer treatment. Curr Drug Discov Technol 2009; 6: 103-134.
113. Zhang H, Pelzer AM, Kiang DT, et al. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007; 67: 391-397.